Form 4: Glaukos Director Denice Torres Receives Equity Grant

Director Denice Torres acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Corporation director compensation policy.

Summary

• Director Denice Torres was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
• The director also received 2,987 stock options with an exercise price of $53.57.
• The total beneficial ownership for the director following these transactions is 24,212 shares.
• Both the RSUs and the stock options are scheduled to vest in full on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation structure under the company's established Director Compensation Policy.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• None identified; this is a standard equity grant disclosure.

Future Outlook

The equity grants are subject to a one-year vesting period, aligning the director's long-term interests with the company's performance through May 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard industry practice in the medical device sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant follows standard corporate governance practices for mid-cap medical technology companies.
• Vesting schedules of one year are consistent with typical director compensation packages in the U.S. healthcare sector.

Stakeholder Impact

• Minimal impact on shareholders as these grants are part of the pre-existing director compensation policy.

Next Steps

• Vesting of the granted RSUs and stock options on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Director Compensation, Equity Grant, Insider Transaction, Form 4